Kinarus Therapeutics Announces Personnel Change
12 juil. 2023 01h00 HE
|
Kinarus Therapeutic Holding AG
Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and...
Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting
29 juin 2023 12h00 HE
|
Kinarus Therapeutic Holding AG
Basel, Switzerland, 29 June 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral,...
Kinarus Therapeutics signed subordinated bridge loans to ensure further liquidity
27 juin 2023 01h00 HE
|
Kinarus Therapeutic Holding AG
Basel, Switzerland, June 26, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and...
Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting
02 juin 2023 01h00 HE
|
Kinarus Therapeutic Holding AG
Basel, Switzerland, 2 June 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral,...
Kinarus Therapeutics Group Reports 2022 Annual Results
31 mai 2023 01h00 HE
|
Kinarus Therapeutic Holding AG
Publishes Annual Report with Audited Consolidated Financial Results for Year Ended 31 December 2022Clinical efforts re-focused on developing KIN001 for original indications IPF and wet AMDCDIM CHF1.5...
Kinarus Therapeutics signed CHF1.5 million convertible loan agreement with ChaoDian (Hangzhou) Investment Management
11 mai 2023 01h00 HE
|
Kinarus Therapeutic Holding AG
Basel, Switzerland, May 10, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and...
Kinarus Therapeutics Reports Key Unaudited Full Year 2022 Figures
05 mai 2023 01h00 HE
|
Kinarus Therapeutic Holding AG
Audited full year 2022 annual financial figures due to be reported by end of May 2023 Basel, Switzerland, May 5, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage...
Kinarus Therapeutics Holding AG ("Kinarus") receives deadline extension from SER for publication of its 2022 annual financial report
28 avr. 2023 01h00 HE
|
Kinarus Therapeutic Holding AG
Ad hoc announcement pursuant to Art. 53 LR Kinarus Therapeutics Holding AG ("Kinarus") receives deadline extension from SER for publication of its 2022 annual financial report Basel, Switzerland, 28...
Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update
21 févr. 2023 01h00 HE
|
Kinarus Therapeutic Holding AG
KINFAST is evaluating KIN001 for reduction in severity and duration of Covid-19 symptomsKINFAST is actively enrolling in Germany/Switzerland Basel, Switzerland, 20 February 2023. Kinarus Therapeutics...
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan
17 janv. 2023 01h00 HE
|
Kinarus Therapeutic Holding AG
KIN001 reduced fibrotic damage of the lung in a preclinical fibrosis modelPotential as an effective oral therapy for Idiopathic Pulmonary Fibrosis (IPF)Phase 2 clinical trial in IPF patients in...